Eudesmin |
| Catalog No.GC61941 |
Eudesmin ((-)-Eudesmin) altère la différenciation adipogénique via l'inhibition de la voie de signalisation S6K1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 526-06-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities[1].
Treatment of mesenchymal stem cells (MSCs) with Eudesmin (20, 40, and 80µM) disturbs adipogenesis via suppression of S6K1 signaling pathway. Eudesmin treatment inhibits activation and nuclear translocation of S6K1. S6K1-mediated phosphorylation of H2B at serine 36 (H2BS36p) is reduced upon Eudesmin treatment[1].
References:
[1]. Ki Hong Nam, et al. Eudesmin Impairs Adipogenic Differentiation via Inhibition of S6K1 Signaling Pathway. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1148-1153.
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *